<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://mpkb.org/lib/exe/css.php?s=feed" type="text/css"?>
<rss version="2.0">
    <channel xmlns:g="http://base.google.com/ns/1.0">
        <title>Marshall Protocol Knowledge Base - home:starting:physician</title>
        <description></description>
        <link>https://mpkb.org/</link>
        <lastBuildDate>Mon, 27 Apr 2026 13:26:01 +0000</lastBuildDate>
        <generator>FeedCreator 1.8</generator>
        <image>
            <url>https://mpkb.org/_media/wiki/dokuwiki.svg</url>
            <title>Marshall Protocol Knowledge Base</title>
            <link>https://mpkb.org/</link>
        </image>
        <item>
            <title>Finding a physician</title>
            <link>https://mpkb.org/home/starting/physician/finding?rev=1656936376&amp;do=diff</link>
            <description>&lt;table&gt;&lt;tr&gt;&lt;th colspan=&quot;2&quot; width=&quot;50%&quot;&gt;06.01.2019&lt;/th&gt;&lt;th colspan=&quot;2&quot; width=&quot;50%&quot;&gt;current&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 27:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 27:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * remaining [[home:starting:usingforum:home|active on the forums]],&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * remaining [[home:starting:usingforum:home|active on the forums]],&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * watching (older) [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://marshallprotocol.com/conferences/|conference broadcasts]], and (lately) [[https://www.youtube.com/user/DrTrevorMarshall|videos]]&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * watching (older) [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://marshallprotocol.com/conferences/|conference broadcasts]], and (lately) [[https://www.youtube.com/user/DrTrevorMarshall|videos]]&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * subscribing to updates from the [[home:index|Marshall Protocol Knowledge Base]].&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * subscribing to updates from the [[home:index|Marshall Protocol Knowledge Base]].&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 51:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 51:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * [[https://www.aaemonline.org//|American Academy of Environmental Medicine]] - professional organization of doctors who use alternative therapies.&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * [[https://www.aaemonline.org//|American Academy of Environmental Medicine]] - professional organization of doctors who use alternative therapies.&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.acam.org/|American College of Advancement in Medicine]] – physicians who take an integrative approach to medicine &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.acam.org/|American College of Advancement in Medicine]] – physicians who take an integrative approach to medicine &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.ama-assn.org/|AMA]] – search for information about virtually every licensed physician in the United States and its possessions — including more than 690,000 doctors of medicine and doctors of osteopathy or osteopathic medicine.&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.ama-assn.org/|AMA]] – search for information about virtually every licensed physician in the United States and its possessions — including more than 690,000 doctors of medicine and doctors of osteopathy or osteopathic medicine.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== Australia and New Zealand ====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== Australia and New Zealand ====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.acnem.org/membership.php|Australian College of Nutrition and Environmental Medicine]]&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.acnem.org/membership.php|Australian College of Nutrition and Environmental Medicine]]&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== On the forums ====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== On the forums ====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.marshallprotocol.com/view_user.php?list=1&amp;amp;letter=&amp;amp;sort_by=location&amp;amp;page=146|example of Marshall Protocol&amp;#039;s members tab]] – Members of the Marshall Protocol site frequently list their city and state/province. The provided link to the MP site is ordered by location - first by country, and then by state/province.&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.marshallprotocol.com/view_user.php?list=1&amp;amp;letter=&amp;amp;sort_by=location&amp;amp;page=146|example of Marshall Protocol&amp;#039;s members tab]] – Members of the Marshall Protocol site frequently list their city and state/province. The provided link to the MP site is ordered by location - first by country, and then by state/province.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Also, members can click on their location under their name in the left column to bring up a list of members with the same location.&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Also, members can click on their location under their name in the left column to bring up a list of members with the same location.&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Patients who are currently on the Protocol are often willing to share their doctors&amp;#039; names via &amp;quot;private message&amp;quot; (PM).&amp;#160; Generally speaking, people who post more often are more likely to be willing to share contact information for their prescribing doctor.&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Patients who are currently on the Protocol are often willing to share their doctors&amp;#039; names via &amp;quot;private message&amp;quot; (PM).&amp;#160; Generally speaking, people who post more often are more likely to be willing to share contact information for their prescribing doctor.&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;{{tag&amp;gt;Starting_the_Marshall_Protocol}}&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;{{tag&amp;gt;Starting_the_Marshall_Protocol&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;research&lt;/strong&gt;}}&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 79:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 79:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Legacy content&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; * Legacy content&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.marshallprotocol.com/forum2/238.html#p22149 e134  &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.marshallprotocol.com/forum2/238.html#p22149 e134  &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.marshallprotocol.com/view_topic.php?id=238&amp;amp;forum_id=2&amp;amp;jump_to=36551#p36551 e141 &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.marshallprotocol.com/view_topic.php?id=238&amp;amp;forum_id=2&amp;amp;jump_to=36551#p36551 e141 &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.marshallprotocol.com/forum2/238.html#p22451 e135&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; &amp;#160; *&amp;#160;&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.marshallprotocol.com/forum2/238.html#p22451 e135&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; &amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&amp;#160; &amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;Joyful&amp;#039;s (updated) recent post:&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;Joyful&amp;#039;s (updated) recent post:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 96:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 96:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;There have been recent updates to this information:&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;There have been recent updates to this information:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://curemyth1.org/forum9/4654.html|Any doctor&amp;#039;s knowledge about the MP is likely very limited]] &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://curemyth1.org/forum9/4654.html|Any doctor&amp;#039;s knowledge about the MP is likely very limited]] &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://curemyth1.org/forum9/4653.html|Success in obtaining a doctor requires preparation]] &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://curemyth1.org/forum9/4653.html|Success in obtaining a doctor requires preparation]] &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://curemyth1.org/forum9/4652.html|How to request a list of doctors in your area]]&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://curemyth1.org/forum9/4652.html|How to request a list of doctors in your area]]&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;We have a special section in the MPKB that provides healthcare providers with the information they need to connect on the forums and to administer the protocol:&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;We have a special section in the MPKB that provides healthcare providers with the information they need to connect on the forums and to administer the protocol:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://mpkb.org/home/physicians|Resources for physicians]] &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://mpkb.org/home/physicians|Resources for physicians]] &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://mpkb.org/home/physicians#support_for_physicians|Support for physicians]] &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://mpkb.org/home/physicians#support_for_physicians|Support for physicians]] &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://mpkb.org/home/physicians#online_forum|How to request access to the Marshall Protocol study site]]&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://mpkb.org/home/physicians#online_forum|How to request access to the Marshall Protocol study site]]&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;From Janet:&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;From Janet:&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
            <author>anonymous@undisclosed.example.com (Anonymous)</author>
            <pubDate>Mon, 04 Jul 2022 12:06:16 +0000</pubDate>
        </item>
        <item>
            <title>Helping a concerned physician to become comfortable with the MP</title>
            <link>https://mpkb.org/home/starting/physician/reluctant?rev=1663188833&amp;do=diff</link>
            <description>&lt;table&gt;&lt;tr&gt;&lt;th colspan=&quot;2&quot; width=&quot;50%&quot;&gt;01.11.2020&lt;/th&gt;&lt;th colspan=&quot;2&quot; width=&quot;50%&quot;&gt;current&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 73:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 73:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Patients experiences =====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Patients experiences =====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;see also https://mpkb.org/home/physicians/concerns#recorded_results_assessed_2013&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== Use words wisely ====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;==== Use words wisely ====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 185:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 186:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&amp;amp;300|4 hourly compared to 6 hourly dosing}}&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&amp;amp;300|4 hourly compared to 6 hourly dosing}}&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:16508590}})) PMID 16508590&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:16508590}})) PMID 16508590&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;short extract for each research study follows:&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;short extract for each research study follows:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:24772521}}))&amp;#160; //&amp;#160; Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:24772521}}))&amp;#160; //&amp;#160; Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:20074257}}))&amp;#160; PMID 20074257&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:20074257}}))&amp;#160; PMID 20074257&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:19304450}}))&amp;#160; &amp;#160;PMID 19304450&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:19304450}}))&amp;#160; &amp;#160;PMID 19304450&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity &amp;amp; apoptosis induction against tumour cells in breast cancer (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:26138656}}))&amp;#160; PMID 26138656&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity &amp;amp; apoptosis induction against tumour cells in breast cancer (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:26138656}}))&amp;#160; PMID 26138656&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;10)&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;10)&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Alzheimer&amp;#039;s disease and dementia1 (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:20068258}}))&amp;#160; PMID 20068258&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Alzheimer&amp;#039;s disease and dementia1 (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:20068258}}))&amp;#160; PMID 20068258&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;prevent migraines (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:12503978}}))&amp;#160; PMID 12503978&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;prevent migraines (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:12503978}}))&amp;#160; PMID 12503978&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;inhibit liver fibrosis and aid liver healing (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:12871826}}))&amp;#160; PMID 12871826&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;inhibit liver fibrosis and aid liver healing (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:12871826}}))&amp;#160; PMID 12871826&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:23775504}} )) PMID 23775504&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:23775504}} )) PMID 23775504&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:30125396}})) PMID 30125396&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:30125396}})) PMID 30125396&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;protect the mitochondria from age-associated damage from oxidation (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:12709417}}))&amp;#160; PMID 12709417&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;protect the mitochondria from age-associated damage from oxidation (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:12709417}}))&amp;#160; PMID 12709417&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;reduce liver fibrosis (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:19303015}}))&amp;#160; PMID 19303015&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;reduce liver fibrosis (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:19303015}}))&amp;#160; PMID 19303015&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;treatment of anxiety and stress-related disorders (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:15837532}}))&amp;#160; PMID 15837532&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;treatment of anxiety and stress-related disorders (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:15837532}}))&amp;#160; PMID 15837532&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;inflammation in myocarditis (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:16336207}}))&amp;#160; PMID 16336207&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;inflammation in myocarditis (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:16336207}}))&amp;#160; PMID 16336207&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:16939632}}))&amp;#160; PMID 16939632&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:16939632}}))&amp;#160; PMID 16939632&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;cytokine damage (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:88888888}}))&amp;#160; PMID&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;cytokine damage (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:88888888}}))&amp;#160; PMID&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:23511341}}))&amp;#160; PMID 23511341&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:23511341}}))&amp;#160; PMID 23511341&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;renal protective effects of olmesartan may be better than those of other ARBs (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:24384547}}))&amp;#160; PMID 23511341&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;renal protective effects of olmesartan may be better than those of other ARBs (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:24384547}}))&amp;#160; PMID 23511341&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:24842388}}))&amp;#160; &amp;#160;PMID 24842388&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:24842388}}))&amp;#160; &amp;#160;PMID 24842388&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* treatment with olmesartan inhibited bone loss (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25363367}}))&amp;#160; PMID 25363367&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* treatment with olmesartan inhibited bone loss (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25363367}}))&amp;#160; PMID 25363367&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25904217}}))&amp;#160; PMID 25904217&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25904217}}))&amp;#160; PMID 25904217&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* decreases viability of malignant cell lines(({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:28666209}}))&amp;#160; PMID 28666209&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* decreases viability of malignant cell lines(({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:28666209}}))&amp;#160; PMID 28666209&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:19124398}}))&amp;#160; PMID 19124398&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:19124398}}))&amp;#160; PMID 19124398&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25891757}}))&amp;#160; PMID 25891757&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25891757}}))&amp;#160; PMID 25891757&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* improvement of glycemic control &amp;amp; insulin resistance was only observed in olmesartan group (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:23303198}}))&amp;#160; PMID 23303198&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* improvement of glycemic control &amp;amp; insulin resistance was only observed in olmesartan group (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:23303198}}))&amp;#160; PMID 23303198&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25275251}}))&amp;#160; PMID 25275251&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25275251}}))&amp;#160; PMID 25275251&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:22418908}}))&amp;#160; PMID 22418908&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:22418908}}))&amp;#160; PMID 22418908&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Recent studies showed treatment with olmesartan inhibited bone loss (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25363367}})),&amp;#160; &amp;#160;PMID 25363367&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Recent studies showed treatment with olmesartan inhibited bone loss (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25363367}})),&amp;#160; &amp;#160;PMID 25363367&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25904217}})),&amp;#160; &amp;#160;PMID 25904217&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25904217}})),&amp;#160; &amp;#160;PMID 25904217&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;decreases viability of malignant cell lines (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:28666209}})),&amp;#160; &amp;#160;PMID 28666209&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;decreases viability of malignant cell lines (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:28666209}})),&amp;#160; &amp;#160;PMID 28666209&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;the volume of larger atherosclerotic plaques (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:19124398}})),&amp;#160; PMID 19124398&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;the volume of larger atherosclerotic plaques (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:19124398}})),&amp;#160; PMID 19124398&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:20202514}}))&amp;#160; PMID 20202514&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:20202514}}))&amp;#160; PMID 20202514&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:27086671}}))&amp;#160; &amp;#160;PMID 27086671&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:27086671}}))&amp;#160; &amp;#160;PMID 27086671&amp;#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25891757}})),&amp;#160; PMID 25891757&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25891757}})),&amp;#160; PMID 25891757&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;improvement of glycemic control &amp;amp; insulin resistance was only observed in olmesartan group (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:23303198}})),&amp;#160; PMID 23303198&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;improvement of glycemic control &amp;amp; insulin resistance was only observed in olmesartan group (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:23303198}})),&amp;#160; PMID 23303198&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25275251}}))&amp;#160; PMID 25275251&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25275251}}))&amp;#160; PMID 25275251&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;we investigated the effects of RNH-6270, an active metabolite of olmesartan, on TNF-α-induced human glomerular EC (HGEC) damage to clarify the renoprotective mechanisms of ARBs. Our findings suggested that olmesartan might have protective effects against TNF-α-induced glomerular EC dysfunction.(({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:&amp;#160; &amp;#160; 23052181}})) PMID 23052181&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;we investigated the effects of RNH-6270, an active metabolite of olmesartan, on TNF-α-induced human glomerular EC (HGEC) damage to clarify the renoprotective mechanisms of ARBs. Our findings suggested that olmesartan might have protective effects against TNF-α-induced glomerular EC dysfunction.(({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:&amp;#160; &amp;#160; 23052181}})) PMID 23052181&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:15124927}}))&amp;#160; PMID 15124927&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.&amp;#160; (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:15124927}}))&amp;#160; PMID 15124927&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in human renal proximal tubular epithelial cells (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:&amp;#160; &amp;#160; 18331441}})) PMID 18331441&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in human renal proximal tubular epithelial cells (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:&amp;#160; &amp;#160; 18331441}})) PMID 18331441&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:21061834}})) PMID 21061834&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:21061834}})) PMID 21061834&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;These data added to our previous results further provide a mechanistic rationale for olmesartan&amp;#039;s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:26240115}})) PMID 26240115&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;These data added to our previous results further provide a mechanistic rationale for olmesartan&amp;#039;s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:26240115}})) PMID 26240115&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. Our results provide insight into the beneficial effects of olmesartan on PO hearts, independent of blood-pressure lowering. [in rat] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:20944640}}))&amp;#160; PMID 20944640&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. Our results provide insight into the beneficial effects of olmesartan on PO hearts, independent of blood-pressure lowering. [in rat] (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:20944640}}))&amp;#160; PMID 20944640&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160;Wistar-Kyoto rats were treated with high-dose olmesartan (3 mg.kg(-1).day(-1)), low-dose olmesartan (0.3 mg.kg(-1).day(-1)) Low-dose ARB had no anti-inflammatory effects in anti-GBM GN. However, high-dose ARB reduced glomerular infiltration of CD8+ cells and ED1+ macrophages and suppressed necrotizing and crescentic lesions by days 5 to 7 (P &amp;lt; 0.05). In addition, high-dose ARB reduced the numbers of ED3+-activated macrophages, suppressed glomerular TNF-α and IFN-γ production, and downregulated M1-related chemokine and cytokines (monocyte chemoattractant protein type 1, IL-6, and IL-12). High-dose ARB also enhanced ED2+ M2 macrophages by day 7 with upregulation of glomerular IL-4 and IL-13 and augmented CCL17, IL-1 receptor antagonist, and IL-10. We concluded that high-dose ARB inhibits glomerular inflammation by increasing the numbers of M2 macrophages and upregulation of anti-inflammatory cytokines and by suppressing M1 macrophage development with downregulation of M1-related proinflammatory cytokines. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:20071465}})) PMID 20071465&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160;Wistar-Kyoto rats were treated with high-dose olmesartan (3 mg.kg(-1).day(-1)), low-dose olmesartan (0.3 mg.kg(-1).day(-1)) Low-dose ARB had no anti-inflammatory effects in anti-GBM GN. However, high-dose ARB reduced glomerular infiltration of CD8+ cells and ED1+ macrophages and suppressed necrotizing and crescentic lesions by days 5 to 7 (P &amp;lt; 0.05). In addition, high-dose ARB reduced the numbers of ED3+-activated macrophages, suppressed glomerular TNF-α and IFN-γ production, and downregulated M1-related chemokine and cytokines (monocyte chemoattractant protein type 1, IL-6, and IL-12). High-dose ARB also enhanced ED2+ M2 macrophages by day 7 with upregulation of glomerular IL-4 and IL-13 and augmented CCL17, IL-1 receptor antagonist, and IL-10. We concluded that high-dose ARB inhibits glomerular inflammation by increasing the numbers of M2 macrophages and upregulation of anti-inflammatory cytokines and by suppressing M1 macrophage development with downregulation of M1-related proinflammatory cytokines. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:20071465}})) PMID 20071465&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan treatment reversed virtually all neuroendocrine and histopathological cardiac changes induced by EAM (We used experimental autoimmune myocarditis in rats) (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:18408131}})) PMID 18408131&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan treatment reversed virtually all neuroendocrine and histopathological cardiac changes induced by EAM (We used experimental autoimmune myocarditis in rats) (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:18408131}})) PMID 18408131&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Treatment with ARB prevents the progression of peritoneal fibrosis and suppresses expression of adhesion molecules in the peritoneum. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:14763058}})) PMID 14763058&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Treatment with ARB prevents the progression of peritoneal fibrosis and suppresses expression of adhesion molecules in the peritoneum. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:14763058}})) PMID 14763058&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;( in cultured human renal proximal tubular cells) Olmesartan inhibited the effect of costimulation with ANG II and IL-6 on AGT expression, indicating that AT1R is critical for AGT enhancement by ANG II. Moreover, IL-6R antibody also neutralized the effect, suggesting that these agents exert a synergistic effect, even though they do not independently induce human AGT expression. These findings suggest that AT1R blockers may attenuate the secondary pathophysiological effects of ANG II even though ANG II alone does not exert any direct effects, and this may partially account for the powerful renoprotective effects of AT1R blocker beyond its depressor effect. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:18463317}}))&amp;#160; PMID 18463317&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;( in cultured human renal proximal tubular cells) Olmesartan inhibited the effect of costimulation with ANG II and IL-6 on AGT expression, indicating that AT1R is critical for AGT enhancement by ANG II. Moreover, IL-6R antibody also neutralized the effect, suggesting that these agents exert a synergistic effect, even though they do not independently induce human AGT expression. These findings suggest that AT1R blockers may attenuate the secondary pathophysiological effects of ANG II even though ANG II alone does not exert any direct effects, and this may partially account for the powerful renoprotective effects of AT1R blocker beyond its depressor effect. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:18463317}}))&amp;#160; PMID 18463317&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (-15.1%; P&amp;lt;0.05), high-sensitivity tumor necrosis factor-alpha (-8.9%; P&amp;lt;0.02), interleukin-6 (-14.0%; P&amp;lt;0.05), and monocyte chemotactic protein-1 (-6.5%; P&amp;lt;0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:15313950}}))&amp;#160; PMID 15313950&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (-15.1%; P&amp;lt;0.05), high-sensitivity tumor necrosis factor-alpha (-8.9%; P&amp;lt;0.02), interleukin-6 (-14.0%; P&amp;lt;0.05), and monocyte chemotactic protein-1 (-6.5%; P&amp;lt;0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:15313950}}))&amp;#160; PMID 15313950&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;Long term treatment Data suggest 40 &amp;amp; 80 mg olmesartan are able to significantly remodel &amp;amp; destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{&lt;strong class=&quot;diff-mark&quot;&gt;pubmed&lt;/strong&gt;&amp;gt;long:25001274}}))&amp;#160; &amp;#160;PMID 25001274&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;Long term treatment Data suggest 40 &amp;amp; 80 mg olmesartan are able to significantly remodel &amp;amp; destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{&lt;strong class=&quot;diff-mark&quot;&gt;pmid&lt;/strong&gt;&amp;gt;long:25001274}}))&amp;#160; &amp;#160;PMID 25001274&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Read more =====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Read more =====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://bacteriality.com/2009/08/10/iom/|Second-guessing the consensus on vitamin D]] – a critical analysis of research used to support increasing population-wide levels of vitamin D supplementation &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://bacteriality.com/2009/08/10/iom/|Second-guessing the consensus on vitamin D]] – a critical analysis of research used to support increasing population-wide levels of vitamin D supplementation &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.rt.com/news/russia-muslim-sect-satarov-213/|Children born and living without sunlight]] – In 2012, it was learned that 27 children had been living underground as members of a Muslim sect. Many had lived there for their entire lives and had never seen daylight. The conditions of these children was pronounced as &amp;quot;satisfactory&amp;quot; by pediatricians. &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.rt.com/news/russia-muslim-sect-satarov-213/|Children born and living without sunlight]] – In 2012, it was learned that 27 children had been living underground as members of a Muslim sect. Many had lived there for their entire lives and had never seen daylight. The conditions of these children was pronounced as &amp;quot;satisfactory&amp;quot; by pediatricians. &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www.topix.net/forum/health/lyme-disease/TLR5VKTCM71F9PEAP|Vitamin D Intolerance]] – &amp;quot;I get sick as a dog.&amp;quot; Lyme and autoimmune patients commiserate with one another over feeling worse after taking vitamin D.  &lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www.topix.net/forum/health/lyme-disease/TLR5VKTCM71F9PEAP|Vitamin D Intolerance]] – &amp;quot;I get sick as a dog.&amp;quot; Lyme and autoimmune patients commiserate with one another over feeling worse after taking vitamin D.  &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;-&lt;/td&gt;&lt;td class=&quot;diff-deletedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;http&lt;/strong&gt;://www2.macleans.ca/2011/10/12/the-truth-about-vitamin-d/|The Truth About Vitamin D]] – plain language summary of the evidence for vitamin D, as of 2011&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;#160; * [[&lt;strong class=&quot;diff-mark&quot;&gt;https&lt;/strong&gt;://www2.macleans.ca/2011/10/12/the-truth-about-vitamin-d/|The Truth About Vitamin D]] – plain language summary of the evidence for vitamin D, as of 2011&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{section&amp;gt;:home:protocol:olmesartan#recent_studies_of_olmesartan_in_patients}}&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{section&amp;gt;:home:protocol:olmesartan#recent_studies_of_olmesartan_in_patients}}&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 323:&lt;/td&gt;
&lt;td class=&quot;diff-blockheader&quot; colspan=&quot;2&quot;&gt;Line 324:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{tag&amp;gt;Starting_the_Marshall_Protocol letters resources_for_physicians}}&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;{{tag&amp;gt;Starting_the_Marshall_Protocol letters resources_for_physicians}}&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;lt;nodisp&amp;gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Notes and comments =====&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;===== Notes and comments =====&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;+&lt;/td&gt;&lt;td class=&quot;diff-addedline&quot;&gt;&amp;lt;/nodisp&amp;gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-lineheader&quot;&gt;&amp;#160;&lt;/td&gt;&lt;td class=&quot;diff-context&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
            <author>anonymous@undisclosed.example.com (Anonymous)</author>
            <pubDate>Wed, 14 Sep 2022 20:53:53 +0000</pubDate>
        </item>
    </channel>
</rss>
